Azathioprine in dermatology: A survey of current practice in the U.K.

British Journal of Dermatology

Volumn 136, Issue 3, 1997, Pages 351-355

  Tan, B B ^a   Lear, J T ^a   Gawkrodger, D J ^b   English, J S C ^a  

^a UNIVERSITY HOSPITAL OF NORTH STAFFORDSHIRE   (United Kingdom)

^b ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; THIOPURINE METHYLTRANSFERASE;

ARTICLE; ATOPIC DERMATITIS; BONE MARROW SUPPRESSION; CARCINOGENICITY; CONTROLLED STUDY; HUMAN; LIVER TOXICITY; MAJOR CLINICAL STUDY; PEMPHIGOID; PRIORITY JOURNAL; SKIN INFLAMMATION;

EID: 0031055794     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2133.1997.tb14942.x     Document Type: Article

References (41)

1. Anstey A. Azathioprine in dermatology: a review in the light of advances in understanding methylation pharmacogenetics. J R Soc Med 1995; 88: 155-60.
2. Snow JL, Gibson LE. A pharmacogenetic basis for the sale and effective use of azathioprine and other thiopurine drugs in dermatologic patients. J Am Acad Dermatol 1995; 32: 114-15.
3. Tidd DM, Patterson ARP. A biochemical mechanism for the delayed cytotoxic reaction of 6-mercaptopurine. Cancer 1974; 34: 738-46.
4. Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 1980; 32: 651-62.
5. Snow JL, Gibson LE. The role of genetic variation in thiopurine methyltransferase activity and the efficacy and/or side effects of axathioprine therapy in dermatologic patients. Arch Dermatol 1995; 131: 193-7.
6. APBI Datasheet Compendium 1995-96. With the Code of Practice for the Pharmaceutical Industry. London: Datapharm Publications Limited: 1929-32.
7. Greaves MW, Burton JL, Marks J, Dawber RPR. Azathioprine in the treatment of bullous pemphigoid. Br Med J 1971; i: 144-5.
8. Burton JL, Harman RMM, Peachey RDG, Warin RP. Azathioprine plus prednisolone in treatment of pemphigoid. Br Med J 1978; 2: 1190-1.
9. Lever WF, Schaumburg-Lever G. Treatment of pemphigus vulgaris. Results obtained in 84 patients between 1961 and 1982. Arch Dermatol 1984; 120: 44-7.
10. Aberer W, Wolff-Schreiner EC, Stingl G, Wolff K. Azathioprine in the treatment of pemphigus vulgaris. A long term follow-up. J Am Acad Dermatol 1987; 16: 527-33.
11. Guillaume J-C, Vaillant L, Bernard P, et al. Controlled trial of azathioprine and plasma exchange in addition to prednisolone in the treatment of bullous pemphigoid. Arch Dermatol 1993; 129: 49-53.
12. August PJ. Azathioprine in the treatment of eczema and actinic reticuloid. Br J Dermatol 1982; 107 (Suppl. 22): 23.
13. Morrison JGL, Schulz EJ. Treatment of eczema with cyclophosphamide and azathioprine. Br J Dermatol 1978; 98: 203-7.
14. Lear JT, English JSC, Jones P, Smith AG. A retrospective review of the use of azathioprine in severe atopic dermatitis. J Am Acad Dermatol 1996; 35: 642-3.
15. Buckley DA, Baldwin P, Rogers S. Azathioprine in severe adult atopic eczema. Br J Dermatol 1995; 133 (Suppl. 45): 18.
16. Sowden J, Berth-Jones J, Ross JS et al. Double-blind, controlled, crossover study of cyclosporin in adults with severe refractory atopic dermatitis. Lancet 1991; 338: 137-40.
17. Berth-Jones J, Finlay A, Zaki I et al. Cyclosporin in severe childhood atopic dermatitis: a multicentre study. Br J Dermatol 1994; 131 (Suppl. 44): 25.
18. Murphy GM, Maurice PDL, Norris PG, et al. Azathioprine treatment in chronic actinic dermatitis: a double-blind controlled trial with monitoring of exposure to ultraviolet radiation. Br J Dermatol 1989; 121: 639-46.
19. Bradley WG, Walton JW. Treatment of dermatomyositis (letter). Br J Med 1976; 2: 43-4.
20. Rowell NR, Goodfield MJD. The connective tissue diseases. In: Textbook of Dermatology (Champion RH, Burton JL, Ebling FJG eds), 5th edn. Vol 3. Oxford: Blackwell Science, 1992: 2276-86.
21. Mcfarlin DE, Griggs RC. Treatment of inflammatory myopathies with azathioprine. Trans Am Neurol Assoc 1968; 93: 244-6.
22. August PJ, Wells GC. Pyoderma gangrenosum treated with azathioprine and prednisolone. Br J Dermatol 1974; 91 (Suppl. 10); 80.
23. Dufill MB. Cyclosporine, azathioprine and local therapy for pyoderma gangrenosum. Australas J Dermatol 1994; 35: 15-18.
24. Lear JT, English JSC. Severe and chronic allergic contact dermatitis responding to azathioprine. J Dermatol Treatment 1996; 7: 109-10.
25. Russell-Jones R. Azathioprine therapy in the management of persistent erythema multiforme. Br J Dermatol 1981; 105: 465-8.
26. Griffiths WAD. Pityriasis rubra pilaris. Clin Exp Dermatol 1980; 5: 105-12.
27. Yazici H, Pazarli H, Barnes CG, et al. A controlled trial azathioprine in Behçet's syndrome. N Engl J Med 1990; 322: 281-5.
28. Singleton JD, West SG, Reddy VV, Rak KM. Cerebral vasculitis complicating rheumatoid arthritis. South Med J 1995; 88: 470-4.
29. Barnett EV, Dornfield L, Dee DBN et al. Long-term survival of lupus nephritis patients treated with azathioprine and prednisolone. J Rheum 1978; 5: 275-87.
30. Callen JP, Spender LV, Burruss JB et al. Azathioprine: an effective, corticosteroid-sparing therapy for patients with recalcitrant cutaneous lupus erythematosus or recalcitrant leucocytoclastic vasculitis. Arch Dermatol 1991; 127: 515-22.
31. Wisehart JM. Wegener's granulomatosis - controlled by azathioprine and corticosteroids. Br J Dermatol 1975; 92: 461-7.
32. Kaplan SR, Calabresi P. Immunosuppressive agents. N Engl J Med 1973; 289: 1234-6.
33. Lear JT, English JSC. Erosive and generalised lichen planus responsive to azathioprine. Clin Exp Dermatol 1996; 21: 56-7.
34. du Vivier A, Munro D, Verbov J. Treatment of psoriasis with azathioprine. Br Med J 1974; 1: 49-51.
35. Silman A, Petrie J, Hazleman B, Evans S. Lymphoproliferative cancer and other malignancy in patients with rheumatoid arthritis treated with azathioprine: a 20 year follow up study. Am Rheum Dis 1988; 47: 988-92.
36. Kinlen LJ, Shiel AGR, Peto J, Doll R. Collaborative United Kingdom-Australasian study of cancer in patients treated with immunosuppressive drugs. Br J Med 1979; 2: 1471-6.
37. Bottomley WW, Ford G, Cunliffe WJ, Cotterill JA. Aggressive squamous cell carcinomas developing in patients receiving long-term azathioprine. Br J Dermatol 1995; 133: 460-62.
38. Connell WR, Kamm MA, Nixon M et al. Long term neoplasia risk after azathioprine treatment in inflammatory bowel disease. Lancet 1994; 343: 1249-52.
39. Lennard L, Lilleyman JS, Van Loon JA et al. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia. Lancet 1990; 336: 225-9.
40. Schutz E, Gummert J, Mohr F et al. Azathioprine-induced myelosuppression in thiopurine methyltransferase deficient heart transplant recipient. Lancet 1993; 341: 436.
41. Mircheva J, Legendre C, Soria-Royer C et al. Monitoring of azathioprine-induced immunosuppression with thiopurine methyltransferase activity in kidney transplant recipients. Transplantation 1995; 60: 639-42.